Frankie Lam

1.1k total citations
20 papers, 889 citations indexed

About

Frankie Lam is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Frankie Lam has authored 20 papers receiving a total of 889 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 13 papers in Oncology and 4 papers in Genetics. Recurrent topics in Frankie Lam's work include Cancer-related Molecular Pathways (11 papers), PI3K/AKT/mTOR signaling in cancer (5 papers) and Cancer Mechanisms and Therapy (4 papers). Frankie Lam is often cited by papers focused on Cancer-related Molecular Pathways (11 papers), PI3K/AKT/mTOR signaling in cancer (5 papers) and Cancer Mechanisms and Therapy (4 papers). Frankie Lam collaborates with scholars based in Australia, United Kingdom and China. Frankie Lam's co-authors include Shudong Wang, Xiangrui Liu, Jinqiang Hou, Christopher G. Proud, Theodosia Teo, Peter M. Fischer, Hao Shao, Mingfeng Yu, Chris Pepper and Robert Milne and has published in prestigious journals such as Journal of Medicinal Chemistry, International Journal of Cancer and British Journal of Pharmacology.

In The Last Decade

Frankie Lam

20 papers receiving 885 citations

Peers

Frankie Lam

ONCOL

PRM

PFM

Mingfeng Yu Australia

Elena Casale Italy

Haridas B. Rode India

Lan-Zhen Wang United Kingdom

Kanami Yamazaki Japan

Zilan Song China

Britta Stordal Ireland

Jin H. Park United States

Matthäus Getlik Germany

Radek Jorda Czechia

Mingfeng Yu Australia

Frankie Lam

674 ×1.4

443 ×1.5

ONCOL

347 ×1.2

273 ×1.4

PRM

167 ×1.5

PFM

Citations per year, relative to Frankie Lam Frankie Lam (= 1×) peers Mingfeng Yu

Countries citing papers authored by Frankie Lam

Since Specialization

Citations

This map shows the geographic impact of Frankie Lam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frankie Lam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frankie Lam more than expected).

Fields of papers citing papers by Frankie Lam

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frankie Lam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frankie Lam. The network helps show where Frankie Lam may publish in the future.

Co-authorship network of co-authors of Frankie Lam

This figure shows the co-authorship network connecting the top 25 collaborators of Frankie Lam. A scholar is included among the top collaborators of Frankie Lam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frankie Lam. Frankie Lam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shao, Hao, David Foley, Shi‐Liang Huang, et al.. (2021). Structure-based design of highly selective 2,4,5-trisubstituted pyrimidine CDK9 inhibitors as anti-cancer agents. European Journal of Medicinal Chemistry. 214. 113244–113244. 18 indexed citations

Lam, Frankie, Long‐Jin Zhong, Theodosia Teo, et al.. (2019). Targeting CDK9 for treatment of colorectal cancer. Molecular Oncology. 13(10). 2178–2193. 41 indexed citations

Zhong, Long‐Jin, Julian Adams, Frankie Lam, et al.. (2018). CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia. Investigational New Drugs. 37(4). 625–635. 30 indexed citations

Taffet, Elliot J., Yoann Olivier, Frankie Lam, David Beljonne, & Gregory D. Scholes. (2018). Carbene–Metal–Amide Bond Deformation, Rather Than Ligand Rotation, Drives Delayed Fluorescence. The Journal of Physical Chemistry Letters. 9(7). 1620–1626. 59 indexed citations

Tadesse, Solomon, Mingfeng Yu, Benjamin Noll, et al.. (2017). Discovery and pharmacological characterization of a novel series of highly selective inhibitors of cyclin‐dependent kinases 4 and 6 as anticancer agents. British Journal of Pharmacology. 175(12). 2399–2413. 20 indexed citations

Tadesse, Solomon, Mingfeng Yu, Laychiluh Mekonnen, et al.. (2017). Highly Potent, Selective, and Orally Bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine Cyclin-Dependent Kinases 4 and 6 Inhibitors as Anticancer Drug Candidates: Design, Synthesis, and Evaluation. Journal of Medicinal Chemistry. 60(5). 1892–1915. 61 indexed citations

Zhang, Wei, Sanjay Garg, Preethi Eldi, et al.. (2016). Targeting prostate cancer cells with genetically engineered polypeptide-based micelles displaying gastrin-releasing peptide. International Journal of Pharmaceutics. 513(1-2). 270–279. 25 indexed citations

Teo, Theodosia, Frankie Lam, Mingfeng Yu, et al.. (2015). Pharmacologic Inhibition of MNKs in Acute Myeloid Leukemia. Molecular Pharmacology. 88(2). 380–389. 27 indexed citations

Teo, Theodosia, Mingfeng Yu, Yuchao Yang, et al.. (2014). Pharmacologic co-inhibition of Mnks and mTORC1 synergistically suppresses proliferation and perturbs cell cycle progression in blast crisis-chronic myeloid leukemia cells. Cancer Letters. 357(2). 612–623. 38 indexed citations

10.

Diab, Sarah, Theodosia Teo, Malika Kumarasiri, et al.. (2014). Discovery of 5‐(2‐(Phenylamino)pyrimidin‐4‐yl)thiazol‐2(3H)‐one Derivatives as Potent Mnk2 Inhibitors: Synthesis, SAR Analysis and Biological Evaluation. ChemMedChem. 9(5). 962–972. 71 indexed citations

11.

Yu, Mingfeng, Julian Adams, Frankie Lam, et al.. (2014). Discovery of (E)-3-((Styrylsulfonyl)methyl)pyridine and (E)-2-((Styrylsulfonyl)methyl)pyridine Derivatives as Anticancer Agents: Synthesis, Structure–Activity Relationships, and Biological Activities. Journal of Medicinal Chemistry. 57(6). 2275–2291. 27 indexed citations

12.

Lam, Frankie, Hao Shao, Theodosia Teo, et al.. (2014). Targeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73. Oncotarget. 5(17). 7691–7704. 45 indexed citations

13.

Shao, Hao, David Foley, Frankie Lam, et al.. (2013). Synthesis, structure–activity relationship and biological evaluation of 2,4,5-trisubstituted pyrimidine CDK inhibitors as potential anti-tumour agents. European Journal of Medicinal Chemistry. 70. 447–455. 50 indexed citations

14.

Shao, Hao, Shi‐Liang Huang, Alison J. Hole, et al.. (2013). Substituted 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidines Are Highly Active CDK9 Inhibitors: Synthesis, X-ray Crystal Structures, Structure–Activity Relationship, and Anticancer Activities. Journal of Medicinal Chemistry. 56(3). 640–659. 104 indexed citations

15.

Lam, Frankie, et al.. (2012). Synthesis and biological evaluation of imidazo[4,5-b]pyridine and 4-heteroaryl-pyrimidine derivatives as anti-cancer agents. European Journal of Medicinal Chemistry. 57. 311–322. 60 indexed citations

16.

Hou, Jinqiang, Frankie Lam, Christopher G. Proud, & Shudong Wang. (2012). Targeting Mnks for Cancer Therapy. Oncotarget. 3(2). 118–131. 119 indexed citations

17.

Chahrour, Osama, Ashraf N. Abdalla, Frankie Lam, Carol Midgley, & Shudong Wang. (2011). Synthesis and biological evaluation of benzyl styrylsulfonyl derivatives as potent anticancer mitotic inhibitors. Bioorganic & Medicinal Chemistry Letters. 21(10). 3066–3069. 15 indexed citations

18.

Lam, Frankie, Tracey D. Bradshaw, Hui Mao, et al.. (2011). ZJU-6, a novel derivative of Erianin, shows potent anti-tubulin polymerisation and anti-angiogenic activities. Investigational New Drugs. 30(5). 1899–1907. 17 indexed citations

19.

Liu, Xiangrui, et al.. (2011). In vitro antitumor mechanism of a novel cyclin-dependent kinase inhibitor CDKI-83. Investigational New Drugs. 30(3). 889–897. 10 indexed citations

20.

Liu, Xiangrui, et al.. (2011). CDKI‐71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol. International Journal of Cancer. 130(5). 1216–1226. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact